Supernus Pharmaceuticals (NasdaqGM:SUPN) - Share price, News & Analysis

SUPN fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	1/6
Financial Health	5/6
Dividends	0/6

SUPN Stock Overview

Rewards

Trading at 78.7% below our estimate of its fair value

Earnings are forecast to grow 24.39% per year

Risk Analysis

Large one-off items impacting financial results

Profit margins (12.2%) are lower than last year (20%)

Supernus Pharmaceuticals Competitors

Prestige Consumer Healthcare

NYSE:PBH

US$2.8b

Pacira BioSciences

NasdaqGS:PCRX

US$2.7b

Amphastar Pharmaceuticals

NasdaqGS:AMPH

US$1.8b

Collegium Pharmaceutical

NasdaqGS:COLL

US$541.9m

Price History & Performance

Summary of all time highs, changes and price drops for Supernus Pharmaceuticals
Historical stock prices
Current Share Price	US$27.27
52 Week High	US$34.50
52 Week Low	US$23.15
Beta	1.13
1 Month Change	-6.90%
3 Month Change	-15.26%
1 Year Change	-9.28%
3 Year Change	-14.81%
5 Year Change	-27.47%
Change since IPO	407.82%

Shareholder Returns

	SUPN	US Pharmaceuticals	US Market
7D	1.2%	1.6%	1.0%
1Y	-9.3%	13.6%	-15.1%

Return vs Industry: SUPN underperformed the US Pharmaceuticals industry which returned 13.5% over the past year.

Return vs Market: SUPN exceeded the US Market which returned -13.2% over the past year.

Price Volatility

Is SUPN's price volatile compared to industry and market?
SUPN volatility
SUPN Average Weekly Movement	5.5%
Pharmaceuticals Industry Average Movement	11.7%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	2.9%

Stable Share Price: SUPN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: SUPN's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2005	575	Jack Khattar	https://www.supernus.com

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company’s commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients.

Supernus Pharmaceuticals Fundamentals Summary

How do Supernus Pharmaceuticals's earnings and revenue compare to its market cap?
SUPN fundamental statistics
Market Cap	US$1.46b
Earnings (TTM)	US$73.35m
Revenue (TTM)	US$601.35m

19.9x

P/E Ratio

2.4x

P/S Ratio

Is SUPN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
SUPN income statement (TTM)
Revenue	US$601.35m
Cost of Revenue	US$78.04m
Gross Profit	US$523.31m
Other Expenses	US$449.96m
Earnings	US$73.35m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	1.37
Gross Margin	87.02%
Net Profit Margin	12.20%
Debt/Equity Ratio	48.3%

How did SUPN perform over the long term?

See historical performance and comparison

Valuation

Is Supernus Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: SUPN ($27.27) is trading below our estimate of fair value ($127.81)

Significantly Below Fair Value: SUPN is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: SUPN is good value based on its Price-To-Earnings Ratio (19.9x) compared to the US Pharmaceuticals industry average (20x).

PE vs Market: SUPN is poor value based on its Price-To-Earnings Ratio (19.9x) compared to the US market (14.9x).

Price to Earnings Growth Ratio

PEG Ratio: SUPN is good value based on its PEG Ratio (0.8x)

Price to Book Ratio

PB vs Industry: SUPN's Price-To-Book Ratio (1.8x) is in line with the US Pharmaceuticals industry average.

Future Growth

How is Supernus Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

24.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SUPN's forecast earnings growth (24.4% per year) is above the savings rate (1.9%).

Earnings vs Market: SUPN's earnings (24.4% per year) are forecast to grow faster than the US market (12.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SUPN's revenue (4.5% per year) is forecast to grow slower than the US market (7.7% per year).

High Growth Revenue: SUPN's revenue (4.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SUPN's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Supernus Pharmaceuticals performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

2.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SUPN has a large one-off loss of $20.2M impacting its March 31 2022 financial results.

Growing Profit Margin: SUPN's current net profit margins (12.2%) are lower than last year (20%).

Past Earnings Growth Analysis

Earnings Trend: SUPN's earnings have grown by 2.2% per year over the past 5 years.

Accelerating Growth: SUPN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SUPN had negative earnings growth (-34%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16.9%).

Return on Equity

High ROE: SUPN's Return on Equity (8.9%) is considered low.

Financial Health

How is Supernus Pharmaceuticals's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: SUPN's short term assets ($568.5M) exceed its short term liabilities ($284.6M).

Long Term Liabilities: SUPN's short term assets ($568.5M) exceed its long term liabilities ($526.5M).

Debt to Equity History and Analysis

Debt Level: SUPN's net debt to equity ratio (10.6%) is considered satisfactory.

Reducing Debt: SUPN's debt to equity ratio has increased from 1.6% to 48.3% over the past 5 years.

Debt Coverage: SUPN's debt is well covered by operating cash flow (23.8%).

Interest Coverage: SUPN's interest payments on its debt are well covered by EBIT (8.6x coverage).

Balance Sheet

Dividend

What is Supernus Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SUPN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SUPN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SUPN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SUPN's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SUPN has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.8yrs

Average management tenure

CEO

Jack Khattar (60 yo)

17.33yrs

Tenure

US$8,116,721

Compensation

Mr. Jack A. Khattar founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as its Chief Executive Officer, President, Secretary and Director since 2005. He serve...

CEO Compensation Analysis

Compensation vs Market: Jack's total compensation ($USD8.12M) is above average for companies of similar size in the US market ($USD5.44M).

Compensation vs Earnings: Jack's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

Leadership Team

Experienced Management: SUPN's management team is seasoned and experienced (6.8 years average tenure).

Board Members

Experienced Board: SUPN's board of directors are seasoned and experienced ( 11.8 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/25 00:00
End of Day Share Price	2022/05/25 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31